Krystal Biotech, Inc. - COMMON STOCK (KRYS) Institutional Ownership

13F Institutional Holders and Ownership History from Q3 2017 to Q4 2025

Type / Class
Equity / COMMON STOCK
Symbol
KRYS on Nasdaq
Shares outstanding
29,067,614
Price per share
$246.54
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
27,965,720
Total reported value
$4,936,826,319
% of total 13F portfolios
0.01%
Share change
+331,302
Value change
+$83,533,511
Number of holders
281
Price from insider filings
$246.54
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Krystal Biotech, Inc. - COMMON STOCK (KRYS) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
STATE STREET CORP 4.4% $219,088,418 1,278,975 STATE STREET CORPORATION 31 Dec 2024

As of 30 Sep 2025, 281 institutional investors reported holding 27,965,720 shares of Krystal Biotech, Inc. - COMMON STOCK (KRYS). This represents 96% of the company’s total 29,067,614 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Krystal Biotech, Inc. - COMMON STOCK (KRYS) together control 82% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
FMR LLC 15% 4,341,447 +0.15% 0.04% $766,395,653
BlackRock, Inc. 13% 3,834,128 -0.29% 0.01% $676,838,615
VANGUARD GROUP INC 9.6% 2,792,208 -1.1% 0.01% $492,908,477
Avoro Capital Advisors LLC 9.6% 2,777,777 +4.4% 6.3% $490,360,974
STATE STREET CORP 4.8% 1,395,967 +3% 0.01% $246,430,055
Soleus Capital Management, L.P. 3.5% 1,018,831 +10% 9.6% $179,854,236
Capital World Investors 2.8% 809,240 -14% 0.02% $142,855,137
Frazier Life Sciences Management, L.P. 2.4% 688,460 0% 3.6% $121,533,844
Redmile Group, LLC 2.3% 661,388 -0.31% 11% $116,754,824
CITADEL ADVISORS LLC 2.2% 636,988 +1743% 0.09% $112,447,492
GEODE CAPITAL MANAGEMENT, LLC 2.1% 611,244 -1.3% 0.01% $107,918,493
Hood River Capital Management LLC 2.1% 606,946 +14% 1.3% $107,144,177
DIMENSIONAL FUND ADVISORS LP 1.8% 533,964 +5.5% 0.02% $94,260,975
BRAIDWELL LP 1.8% 520,401 -28% 2.7% $91,866,389
PRICE T ROWE ASSOCIATES INC /MD/ 1.6% 467,058 +79% 0.01% $82,451,000
GOLDMAN SACHS GROUP INC 1.2% 348,250 -34% 0.01% $61,476,572
FIRST TRUST ADVISORS LP 0.85% 248,392 +12% 0.03% $43,848,639
NORTHERN TRUST CORP 0.85% 248,165 -1.3% 0.01% $43,808,568
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.84% 242,863 -1.3% 0.01% $42,872,605
MORGAN STANLEY 0.81% 234,577 +0.07% 0% $41,409,913
UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC 0.7% 202,589 -14% 0.01% $35,763,036
Nuveen, LLC 0.68% 197,378 +5% 0.01% $34,843,139
Pictet Asset Management Holding SA 0.68% 196,904 +51% 0.03% $34,759,463
Bank of New York Mellon Corp 0.54% 155,553 -3.1% 0% $27,459,720
Woodline Partners LP 0.52% 150,616 0% 0.13% $26,588,242

Institutional Holders of Krystal Biotech, Inc. - COMMON STOCK (KRYS) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 148,751 $36,882,392 -$870,448 $246.54 31
2025 Q3 27,965,720 $4,936,826,319 +$83,533,511 $176.53 281
2025 Q2 27,659,439 $3,802,977,476 -$846,433 $137.46 274
2025 Q1 27,342,861 $4,929,918,722 -$51,223,785 $180.30 298
2024 Q4 27,773,780 $4,351,749,266 -$54,066,261 $156.66 263
2024 Q3 28,035,360 $5,103,209,928 -$100,176,675 $182.03 282
2024 Q2 28,493,216 $5,232,325,944 +$661,046,286 $183.64 247
2024 Q1 25,207,926 $4,485,083,071 +$195,256,146 $177.93 238
2023 Q4 65,797 $8,230,116 +$4,011,945 $125.91 2
2023 Q3 23,774,399 $2,757,917,313 +$92,586,966 $116.00 184
2023 Q2 23,015,574 $2,701,916,350 +$256,395,935 $117.40 179
2023 Q1 20,972,441 $1,678,422,349 +$9,461,385 $80.06 156
2022 Q4 20,890,112 $1,654,943,527 -$15,779,448 $79.22 150
2022 Q3 20,762,502 $1,447,227,739 +$2,327,569 $69.70 136
2022 Q2 20,777,076 $1,364,144,880 +$17,499,345 $65.66 127
2022 Q1 20,336,405 $1,353,237,049 +$79,480,206 $66.54 124
2021 Q4 19,120,259 $1,337,480,574 +$208,170,957 $69.95 133
2021 Q3 16,291,430 $850,665,590 -$12,045,225 $52.21 112
2021 Q2 15,634,343 $1,063,130,700 -$6,338,466 $68.00 112
2021 Q1 16,474,375 $1,268,578,569 +$169,825,255 $77.04 113
2020 Q4 12,658,746 $760,015,340 -$25,499,094 $60.00 103
2020 Q3 14,383,049 $619,120,442 +$11,303,610 $43.05 97
2020 Q2 14,056,265 $582,204,548 +$105,808,809 $41.42 105
2020 Q1 11,460,717 $495,564,700 -$10,497,508 $43.24 86
2019 Q4 11,391,925 $630,888,478 +$15,761,601 $55.38 89
2019 Q3 11,179,428 $388,217,616 +$48,358,005 $34.73 81
2019 Q2 9,759,473 $392,969,789 +$130,951,195 $40.27 73
2019 Q1 6,652,555 $218,869,000 +$15,470,941 $32.90 56
2018 Q4 6,208,589 $129,016,000 +$67,891,549 $20.78 45
2018 Q3 2,092,290 $36,609,000 -$4,980,161 $17.57 20
2018 Q2 2,390,144 $35,542,000 -$7,829,429 $14.87 15
2018 Q1 3,076,255 $31,040,000 -$1,629,990 $10.09 12
2017 Q4 3,236,349 $34,047,000 +$1,027,243 $10.52 13
2017 Q3 3,142,571 $31,331,000 +$31,331,000 $9.97 13